THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more ...
An Academic Perspective to First-Line Treatment Decisions for EGFR-mutated Advanced/Metastatic NSCLC
The panelist discusses how, when discussing first-line treatment decisions for cancer patients, healthcare professionals primarily consider patient-specific factors like disease stage, molecular ...
Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...
FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback